Novartis Bags Another Bolt-On With Cadent Buy
Pays $210m Upfront For Cognitive Disorder Biotech
Having worked with the Cambridge, MA-based neurology specialist for five years on a treatment-resistant depression drug, Novartis has decided to buy all of Cadent in a deal that could be worth up to $770m.
You may also be interested in...
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.
The troubled Belgian biotech has pulled off a major coup in hiring Paul Stoffels, the architect of J&J's R&D successes over the last decade, as its new CEO.